How to treat adverse gastrointestinal cancer -related gastrointestinal cancer?The first -line chemotherapy is not spiritual, and the immunotherapy disease relief | August 31st Jinling Lung Cancer Network Forum is here!

*For medical professionals for reading reference

Seeing immunotherapy brings new vitality to patients with lung cancer!

How to diagnose and judge the source in time? How to choose pulmonary mucus cancer treatment schemes? Surgery of primary pulmonary adenocarcinoma after radiotherapy, surgery or systemic treatment? How to treat immunotherapy -related gastrointestinal tract adverse reactions?

Last review

Professor Leng Zaijun of the First Affiliated Hospital of China University of Science and Technology brings a case of lung cancer specifications that survive for more than 5 years. EGFR-TKI has become a first-line standard treatment plan for driving gene-positive non-small cell lung cancer (NSCLC), but many patients in the treatment process will have drug resistance. The patient's progress (PD) after the treatment of Gibitinib (PD), switched to three generations of EGFR-TKI Oshitinib for treatment again, and a brain metastases. How should the next step formulate a treatment strategy? Can chemotherapy+Bevarzumab benefit? Is the potential beneficiary of patients immunotherapy? What treatment plan makes patients exceed 60 months after repeated progress?

Professor Zhu Bingjing from the First Affiliated Hospital of the Army Military Medical University brought a case of small cell lung cancer related to immunotherapy related to ECG. The patient's first and second lines use chemotherapy. Although it is partially relieved (PR) after treatment, PD still occurs. Unexpectedly, the driving gene mutations were obtained, and the PD-L1 expression level was high, and immunotherapy was used. For more than July after immunotherapy, patients have myocarditis. What should I do at this time? Immunotherapy -related carditis has a low incidence and high mortality. Is there any related risk factors predictable? How to find it early?

Professor Wang Xiaofei from Ruijin Hospital affiliated to Shanghai Jiaotong University brought a case of phase IIIA cancer cases for immunochemical combined chemotherapy. After consultation with MDT, the patient considers the white protein paclitaxel+card platinum+Paborizumab newly adjusted therapy, and then seriously immune -related skin adverse reactions occur. What should I do for immune -related skin adverse reactions? After the new auxiliary therapy was over, the lobe cutting was removed with lymph nodes, and the postoperative evaluation was fully relieved (PCR). IIIA's new auxiliary treatment and synchronous chemotherapy+immunotherapy after the treatment of lung squamous cell carcinoma after treatment, which solution can obtain greater OS benefits? Immunotherapy -related adverse reactions are closely related to curative effect?

Last review

Professor Wang Peng of the Second Medical Center of the PLA General Hospital brought a case of pulmonary mucus cancer. Patients were diagnosed with lung cancer and liver metastasis. After being treated with lung nodules and nodules, lung lesions progressed, and liver new stoves were caused. The pathological diagnosis of liver lesions is a non -Hodgkin lymphoma, which has reached a complete relief (CR) after treatment. The diagnosis of pulmonary lesions is lung infiltrated mucous glandular cancer (intestinal type). How to diagnose multiple tumors? How to treat pulmonary mucus cancer in the next step?

Professor Gao Fang of Henan Cancer Hospital brought a case of recurrent lung adenocarcinoma. Patient, male, 80 years old. The first diagnosis of primary lung adenocarcinoma was found after April after root radiotherapy, and the cecum metastasis was found. After testing, tumor tissue PD-L1 TPS 80%. At this time, how should the patient's TNM staging be judged? Surgery, or whole -body treatment, how to formulate subsequent treatment plans for patients?

Professor Xu Liqin at Nantong University Affiliated Hospital brought a case of lung squamous carcinoma. Patients were diagnosed with phase ichthytoma carcinoma IIIB, while suffering from hypertension. After two treatment chemotherapy, the disease continued to progress. At this time, the patient was treated with Paborizumab. After four courses, the patient had adverse reactions in immune -related. How should we manage the adverse reactions of immunity?

The first release of this article: the medical world tumor channel

Author of this article: Cat on the window sill

Editor in charge: Sweet

- END -